29
Feb
2016
One Way to Improve Clinical Trials: A Yelp-Style Rating System
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Feb
2016
‘Quit Whining’ and 11 Other Ways Industry Should Communicate Better
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Feb
2016
Why Patents Are Sometimes Overrated
You could get the impression, reading about the patent fight over the CRISPR-Cas9 genome editing, that patents are the only thing that matter in biotech. Once the courts sort out who the rightful inventors are, that’s that. The winner gets fame and fortune. Losers get a set of steak knives, or fired. All or nothing. This is a reasonable view... Read More
5
Feb
2016
Are You Ready for Some Football? Maybe Yes, Maybe No
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Feb
2016
As the Smirk Turns, FDA’s Opioid Plan, And A Gene Editing IPO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Feb
2016
A Short History of Cures for Hepatitis C
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Jan
2016
Competition Alone Won’t Cut It On Drug Prices
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Dec
2015
OrbiMed Reloads, Bayer’s CRISPR Foray & Some Good Longreads
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Dec
2015
Shkreli Gets Pinched, Cruz Tries to Kneecap FDA & Woodford’s Nutty Investment
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Dec
2015
Family Offices: A Quiet, Emerging Force in Biotech Investing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Nov
2015
Commentary on the FDA Duchenne Panel With Meg Tirrell
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Nov
2015
Pursuing a Hard Cancer Target: Q&A With Warp Drive CEO Laurence Reid
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Nov
2015
Raiding the Talent at Pfizer: Where Might The R&D Brains Go?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Nov
2015
D.C. Crosshairs on Pharma, ASH Roller Coaster & An IPO Cooldown
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Oct
2015
Pfizer’s New MegaMerger Target, Valeant Burns & Amgen’s Cancer Advance
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Oct
2015
Investors Shouldn’t Nitpick Old Data. Bluebird’s New Gene Therapy Vector Makes a Difference
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Oct
2015
Theranos Exposed, Lilly Cholesterol Drug Flops & 23andMe Raises More Dough
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Oct
2015
The Immune System as a Metaphor for the Turing Pharma Mess
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Oct
2015
The Next Macro (Phage) Thing in Immuno-Oncology
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Sep
2015
Just Snags $15M From Merck, Lilly, ARCH for Low-Cost Biotech Drugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.